Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cordis corporate warning letter resolved

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's stent subsidiary finally resolves a 2004 corporate warning letter with FDA June 14. Agency inspectors had cited Cordis for quality systems noncompliance, particularly issues relating to handling of safety complaints with the Cypher drug-eluting stent at five different facilities (1"The Gray Sheet" April 12, 2004, p. 3). The company does not expect any new FDA approvals soon as a direct result of the warning letter resolution; Cordis' Precise carotid stent had been held up by the warning letter, but that product was approved last October...

You may also be interested in...



Cypher Warning Letter Cites Systemic GMP Problems At Multiple Facilities

Johnson & Johnson/Cordis' inability to provide timely failure analysis reports of Cypher-related thrombosis complaints is one of several GMP violations cited in an April 1 FDA 1warning letter

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

QUOTED. 17 February 2020. Ralph Ives.

The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.   

UsernamePublicRestriction

Register

MT024911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel